Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Key Financial Performance
Revenue Revenue grew 33% year-over-year and 10% sequentially with net revenues of $9.7 million. This growth reflects disciplined execution, an overhauled go-to-market strategy, and the addition of 14 new accounts, including large community oncology groups.
Net Product Sales Net product sales were $9.7 million, representing a 33% increase compared to the same period last year and 10% growth over the first quarter of this year. This growth is attributed to successful retention of existing customers and new uptake in demand for PEDMARK.
Cash Operating Expenses Total cash operating expenses for the quarter were approximately $11 million, an increase of roughly $2 million compared to the first quarter of this year. The increase was driven by ongoing investments in marketing, additional headcount, and intellectual property efforts.
Selling and Marketing Expenses Selling and marketing expenses were $4.4 million in the second quarter of 2025 compared to $2.9 million in the first quarter of 2025 and $4.7 million in the second quarter of 2024. The increase was primarily due to additional marketing expenses and a one-time accrual reversal in Q1 2025.
General and Administrative (G&A) Expenses G&A expenses were $7 million in the second quarter of 2025 compared to $6.1 million in the first quarter of 2025 and $6.9 million in the second quarter of 2024. The increase was largely due to increased noncash stock compensation and ongoing litigation and intellectual property expenses.
Cash and Cash Equivalents Cash and cash equivalents were approximately $18.7 million as of June 30, 2025. The company expects full-year cash operating expenses to be similar to 2024, roughly $33 million, with potential increases in cash balance from product revenues, milestones, and partnerships.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PEDMARK adoption: PEDMARK is the first and only FDA-approved therapy in the U.S. and Europe to reduce the risk of cisplatin-induced ototoxicity (CIO). It has been added to the formulary of a large national oncology group for patients under 40 years of age. NCODA issued a positive quality intervention (PQI) for PEDMARK, providing practical guidance for its use.
Revenue growth: Net revenues for Q2 2025 were $9.7 million, a 33% year-over-year increase and 10% sequential growth. This marks the third consecutive quarter of growth.
Market expansion in Europe: PEDMARK (marketed as PEDMARQSI) has launched in the United Kingdom and Germany through a partnership with Norgine, with positive traction reported.
Operational efficiencies: The company has revamped its go-to-market strategy, resulting in disciplined execution and scalability. Investments in marketing, headcount, and intellectual property have been made to support growth.
Cost management: Cash operating expenses for Q2 2025 were $11 million, with expectations for these expenses to decrease in the second half of 2025. The company aims for cash profitability as revenues grow and expenses decline.
Strategic focus on PEDMARK: Efforts are concentrated on establishing PEDMARK as the standard of care for CIO prevention through education, advocacy, and multidisciplinary engagement.
Leadership and team restructuring: New leadership team members have been brought in to drive strategy, marketing, and medical education, contributing to the company's progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption Challenges: Despite progress, there is still a need to further cement PEDMARK as the standard of care for CIO prevention, which indicates potential challenges in achieving widespread adoption among healthcare providers.
Regulatory and Intellectual Property Risks: The company faces ongoing litigation and intellectual property expenses, which could impact financial stability and operational focus.
Financial Sustainability: The company reported $11 million in cash operating expenses for the quarter, exceeding its net product sales of $9.7 million, raising concerns about financial sustainability and profitability.
Dependence on Partnerships: The company’s financial outlook partially depends on milestones and royalties from its partnership with Norgine, as well as potential monetization or partnerships in Japan, which introduces dependency risks.
Operational Cost Management: Increased marketing and headcount expenses, along with higher G&A costs, could strain resources if revenue growth does not keep pace.
Economic and Market Uncertainties: The company’s growth projections are contingent on market conditions and the successful execution of its commercial strategies, which are subject to external economic factors.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth Expectations: The company anticipates the most significant quarterly growth in the second half of 2025, driven by foundational pillars and initiatives implemented to optimize PEDMARK's growth.
PEDMARK Expansion: Fennec expects additional accounts within large community oncology networks to activate and prescribe PEDMARK in Q3 2025, reflecting growing demand and scalability of the model.
European Market Expansion: The launch of PEDMARQSI by Norgine in the EU is underway in the United Kingdom and Germany, with updates on milestones and royalties expected in future quarters.
Japan Study Results: The company plans to release results from the Japan study in Q4 2025, which may lead to potential monetization or partnership opportunities.
Cash Operating Expenses: Cash operating expenses are expected to decrease in the second half of 2025, aligning with the company's aim towards cash profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Would you guys be willing to share the number of active prescribers, particularly within AYA?
A:Jeffrey S. Hackman stated that they do not share the cumulative number of active prescribers for various reasons. He mentioned that they might consider sharing such data in future quarters but emphasized the need to protect relationships with accounts.
Q:Can you provide visibility into how many patients within AYA accounts are treated with cisplatin and the overall opportunity in those accounts?
A:Jeffrey S. Hackman mentioned that the AYA market is 10 times the size of the pediatric market, with about 20,000 patients aged 15 to 39 treated with cisplatin. Robert C. Andrade added that growth is driven by successful administration, awareness, and reimbursement, with 14 new accounts added in Q2.
Q:What is the cadence of increased writing from an account that starts with a single patient?
A:Jeffrey S. Hackman explained that growth in Q2 was driven by expanding current accounts after initial successful administration of PEDMARK therapy. He emphasized that oncology practices often have multiple cisplatin patients, and efforts are focused on expanding within these practices.
Q:Could you share the amount of royalty revenue from Norgine in the quarter and thoughts on the ramp with your partner?
A:Robert C. Andrade stated that the royalty revenue from Norgine was not material enough to impact financials but showed significant sequential traction, particularly in the U.K. He mentioned plans to expand to broader EU5 markets and Nordic regions later this year and early next year.
Q:Can you provide color on the mix of new and repeat customers?
A:Jeffrey S. Hackman noted that initially, most customers were new, but in Q2, there was a shift toward higher percentages of repeat customers. He mentioned 14 new accounts and emphasized the importance of growing both new and repeat customer bases.
Q:Could you elaborate on the Japanese market opportunity and plans for a potential commercial rollout?
A:Jeffrey S. Hackman stated that Japan represents about one-third the size of the U.S. and Europe in CIO usage. They are analyzing trial data and exploring regulatory and partnership strategies. He emphasized the need for a local partner for regulatory submission and plans to move quickly to avoid delays in product availability.
Q:Do you anticipate operating expenses to remain stable in the second half of the year?
A:Robert C. Andrade mentioned that cash operating expenses are expected to decrease in the second half of the year, with full-year expenses consistent with 2024 levels. He noted that some contracts are structured with upfront payments, leading to higher expenses in the first half.
Q:Can you provide additional color on getting the PQI and how it differs from NCCN guidelines?
A:Jeffrey S. Hackman explained that PQIs are peer-reviewed guidance documents focused on patient care and oncology practices, offering more specific recommendations than NCCN guidelines. He emphasized the importance of having a PQI for PEDMARK to enhance accessibility and standardize care.
Q:How are you splitting marketing resources between the AYA opportunity and the pediatric population?
A:Jeffrey S. Hackman stated that while the AYA market is larger, they continue to focus on both markets, especially in academic institutions. Robert C. Andrade added that relationships in one market often open doors in the other, creating growth potential in both.
Q:How proactive has the FDA been in ensuring compliance with its guidance not to substitute PEDMARK with compounded versions?
A:Jeffrey S. Hackman mentioned that the FDA has been supportive of using FDA-approved products like PEDMARK and that they utilize the FDA's statement when addressing compounding issues. Robert C. Andrade added that there has been no compounded use of PEDMARK in the AYA space.
Q:What is the timeline for Norgine's expansion in the EU?
A:Robert C. Andrade stated that Norgine has launched in the U.K. and Germany, with broader EU5 markets (Italy, Spain, France) and Nordic countries expected to launch later this year and early next year. He emphasized the positive early engagement and traction in the U.K.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for active prescribers and royalty revenue from Norgine, citing reasons such as protecting relationships and the immateriality of the revenue. They also refrained from giving exact percentages for the mix of new and repeat customers, describing it as a moving target.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO
Cancer Awareness
HEARS
NCODA
PEDMARK patient
PEDMARK standard
PQI
Research Division
account
activation
adult patient
age
approach
bell
cisplatin ototoxicity
community oncology
family
healthcare provider
hearing loss
loss cisplatin
need
network PEDMARK
nurse
oncologist
oncology group
payer
peer
pharmacist
prevention
program
quality
risk CIO
service
side
standard care
team
therapy
use
FENC Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
FENC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
